

South West Vaccination & Screening Bulletin


South West Collaborative
Commissioning Hub



Issue 171: 2nd February 2024

Contents:

SCREENING:

- [No items](#)


VACCINATIONS:

- [Conversations to build trust in vaccines: videos and resources for Healthcare Professionals](#)
- [Three new PGDs authorised](#)
- [MMR Eligibility and Schedule Guidance for Healthcare Professionals](#)

COVID-19:

- [End of the Autumn/Winter COVID-19 Vaccination Campaign – Actions Required](#)
- [Covid-19 Vaccination Bulletin - 01 February 2024](#)

FURTHER INFORMATION



SCREENING:

No items

VACCINATIONS:

Conversations to build trust in vaccines: videos and resources for Healthcare Professionals

Dear healthcare professionals,

In the ongoing fight against preventable diseases, as trusted voices in healthcare you play a vital role in encouraging vaccine confidence and empowering informed decisions among your patients.

We understand the crucial conversations you have with patients every day and to support you in this important task we're excited to share **new resources to boost your vaccine confidence conversation skills**.

Whether you want to learn about how to apply Making Every Contact Count or Motivational Interviewing approaches in your vaccine conversations or want to brush up on conversational techniques we've got something for you.

[Click here](#) to access our vaccine confidence resources where you will find a 3-part video about 'Conversations to build trust in vaccines'. We also developed resource packs to provide further guidance on some of our immunisation programmes.

By accessing these resources, you can:

- Strengthen your skills in addressing low vaccine confidence with evidence-based information and effective communication techniques.
- Build trust and rapport with your patients, leading to more informed vaccine decisions.

- Contribute to increased vaccination uptake and improved public health outcomes.

We hope you find these resources valuable! We encourage you to explore these resources and share them with your colleagues.

If you need to access the Vaccination and Screening workspace simply click 'request access' and await the verification email to be added to this workspace. If you require support in registering for a FutureNHS account please visit <https://future.nhs.uk/>

Together, we can make a difference. Let's empower our patients and protect our communities, one conversation at a time.

We'd love to hear your thoughts! Please share your feedback by completing [the survey](#) that will help us in improving the content, delivery and overall experience for all participants.

If you have any questions. please do not hesitate to contact NHSE SW Vaccination and Screening Team england.swvast@nhs.net

Three new PGDs authorised

This article relates to NHS vaccinations. Please share this information with appropriate staff in your practice.

Your team can now download a new Patient Group Direction (PGD) that has been authorised for the vaccination of patients registered with NHS medical practices in the South West of England.

<https://www.england.nhs.uk/south/info-professional/pgd/south-west/downloads/>

Before staff use this, your organisation should ensure that those members of staff have signed section 7, and that this has been counter-signed by an authorising manager.

Note that PGDs can only be used as legal authorisation for administration or supply of prescription-only medicines by a [limited number](#) of registered health professions. Other staff that cannot prescribe will require a patient specific direction (guidance [here](#)).

Three new PGDs have been authorised for a range of registered healthcare professionals to use:

Measles, Mumps and Rubella (MMR) vaccine PGD, V5.00 (MMRVAXPRO® or Priorix®) – valid from 29 February 2024

For the administration of measles, mumps and rubella (MMR) vaccine to individuals from one year of age for routine immunisation, or from 6 months of age if early protection is required, in accordance with the national immunisation

programme and the [National measles guidelines](#), as per The Green Book [chapter 21 \(measles\)](#), [chapter 23 \(mumps\)](#) and [chapter 28 \(rubella\)](#).

Changes from V4.00:

- include minor rewording of standard text, layout and formatting changes for clarity and consistency with organisation change, gateway requirements and other UKHSA PGDs
- amend NHS England and NHS Improvement (NHSEI) to NHSE following completion of merger on 1 July 2022
- replace Public Health England and PHE with UKHSA, including updated contact details
- include updated references, including the National measles guideline 2023
- include detail of phenylalanine content in the vaccine and National Society for Phenylketonuria (NSPKU) advice
- clarify dose schedule for individuals vaccinated before the age of one
- include updated adverse effect profile and expected physical appearance upon reconstitution for Priorix® and MMRVAXPRO®
- update information on co-administration of MMR with varicella and varicella zoster vaccines

Pneumococcal Polysaccharide Conjugate Vaccine (PCV) PGD, V5.00
(Prevenar 13® or Vaxneuvance) – **valid from 28 February 2024**

For the administration of pneumococcal polysaccharide conjugate vaccine (13-valent or 15-valent, adsorbed) (PCV) to individuals from 12 weeks to under 2 years of age in accordance with the national immunisation programme for active immunisation against pneumococcal disease and to individuals from 6 weeks of age recommended PCV13 or PCV15 in response to an outbreak of pneumococcal disease, as per [The Green Book, chapter 25 - Pneumococcal](#).

Changes from V4.00:

- minor rewording, layout and formatting changes for clarity and consistency with other UKHSA PGDs
- new PCV15-valent vaccine (Vaxneuvance®)
- updated temperature excursion information for Prevenar®13
- update of adverse reactions in common to both PCV vaccines
- clarify that outbreak doses are considered additional to the routine immunisation programme for unimmunised or partially immunised children under 2 years of age

Pneumococcal Polysaccharide Conjugate Vaccine (PCV) Risk Groups PGD, V5.00 (Prevenar 13®) – **EXTENSION OF VALIDITY**

This provides notice of extension of the validity of the above PGD until 28 February 2025.

Typhoid Vi Polysaccharide Vaccine PGD, V4.00 (TYPHIM Vi®) – **valid from 29 February 2024**

For the administration of typhoid Vi polysaccharide vaccine to overseas travellers at risk of exposure to *Salmonella enterica serovar typhi* (*S. typhi*) in accordance with recommendations from the National Travel Health Network and Centre ([NaTHNaC](#)) and [The Green Book, chapter 33 - Typhoid](#).

Changes from V3.00:

- include minor rewording, layout and formatting changes for clarity and consistency with other UKHSA PGDs
- update the incidence of known adverse reactions following vaccination with typhoid Vi polysaccharide vaccine
- include details of NaTHNaC advice line

MMR Eligibility and Schedule Guidance for Healthcare Professionals

As you may be aware, the [UKHSA have declared a national incident for measles](#) following an increase in confirmed cases in London and the West Midlands. They have highlighted the need to increase MMR uptake in areas with low coverage to reduce the risk of further outbreaks across the country. The national MMR call/recall campaign for 1-5 year olds has also been extended to include 6-11 year olds.

We appreciate that as a result, practices are receiving a higher-than-normal number of enquiries from patients. To support you with answering their questions and maximise MMR uptake, we have produced a guide to MMR schedule and eligibility for Healthcare Professionals (please find attached). This includes details of the routine schedule, eligibility and exceptions for MMR and some FAQs. Also attached is a checklist for practice nurses to support the national call/recall campaign.

This guide is also available on our FutureNHS site, along with a range of other MMR resources, here: [MMR - SW VaST - FutureNHS Collaboration Platform](#)

You may also find our Guidance on increasing confidence in vaccinations useful: [Vaccine Confidence - SW VaST - FutureNHS Collaboration Platform](#)

If healthcare professionals have any clinical questions about MMR that are not covered in the attached guide, please contact our Immunisation Clinical Advice and Response Service (ICARS) england.swicars@nhs.net.

COVID-19:

End of the Autumn/Winter COVID-19 Vaccination Campaign – Actions Required

The Autumn/Winter 2023/24 COVID-19 vaccination campaign ended on 31st January 2024. If your site will not be offering year-round vaccination to severely

immunosuppressed individuals, please now dispose of any unused COVID-19 vaccine in line with your local standard procedures for disposal of vaccine. All disposals must be recorded in Foundry's Site Stock Manager under the wastage report. All fields should be accurately completed, including batch number, expiry date, quantity (in either doses or vials), category and reason.

The Patient Group Directions (PGDs) and National Protocols to support the Autumn/Winter 2023/24 COVID-19 vaccination campaign have been withdrawn from the [NHSE](#) and [UKHSA](#) webpages. A Patient Specific Direction will be required to support vaccination on a case-by-case basis for severely immunosuppressed individuals, in line with the [Green Book Chapter 14a](#). All sites should archive any printed copies of the Autumn/Winter 2023/24 PGDs and National Protocols to avoid any inappropriate use.

Covid-19 Vaccination Bulletin - 01 February 2024

Please find attached the COVID-19 Vaccination Bulletin from NHS England. This provides need-to-know information from the national COVID-19 vaccination deployment team, supporting Vaccination Centres (VC), Local Vaccination Services (LVS) and Hospital Hubs across the country to deliver the COVID-19 vaccination programme.

If you have any queries, please contact your SVOC who can escalate via the SVOC/RVOC escalation route, if required.

FURTHER INFORMATION

- If you have any questions or feedback about this bulletin, please contact the SW Vaccination & Screening Team at england.swvast@nhs.net. Back issues are available [here](#).
- For advice about Section 7A or COVID-19 vaccinations, or for support following an immunisation incident, please contact ICARS at england.swicars@nhs.net. For more information, please click [here](#).
- For general enquiries, screening related matters or Section 7A public health contracts, please contact england.swvast@nhs.net or [visit our website](#).
- For CQRS payment queries, please contact england.swcqrs@nhs.net.
- **Please note:** if there are no items for your information, a Bulletin will not be circulated.